RCT | Stopping vs. continuing long-term mepolizumab treatment in severe eosinophilic asthma.

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) – European Respiratory Journal

Commentary: Exacerbations Increased After Discontinuing Long-term Use of Mepolizumab for Severe Eosinophilic Asthma – Consultant 360

Commentary on Twitter

This randomised study demonstrates increased exacerbation risk and a decrease in asthma control in patients with severe eosinophilic asthma who stop mepolizumab treatment after long-term use, when compared with those who continue treatment. https://t.co/HYCH0TsU9E pic.twitter.com/rW6hmHgJlj

— ERS publications (@ERSpublications) January 6, 2022